T. Aittokallio

Small molecule STAT3/5 inhibitors exhibit therapeutic potential in acute myeloid leukemia and extra-nodal natural killer/T cell lymphoma

This study evaluates small molecule STAT3/5 inhibitors for treating AML and NKCL, showing growth arrest and synergy with existing therapies in vitro and in vivo.

STAT5 Gain-of-Function Variants Promote Precursor T-Cell Receptor Activation to Drive T-Cell Acute Lymphoblastic Leukemia

This study identifies STAT5 gain-of-function mutations as drivers of T-ALL by promoting pre-TCR signaling and shows therapeutic targeting potential with STAT3/5 or ZAP70 inhibitors.

A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing drugs in RB1-deficient ovarian and breast cancer cells

This study identifies CK2 inhibition as a sensitizing strategy for RB1-deficient ovarian and breast cancer cells to replication-perturbing drugs, showing enhanced efficacy when combined with existing therapies.

Pharmacological PP2A reactivation overcomes multikinase inhibitor tolerance across brain tumor cell models

This study identifies a triplet therapy combining AKT, PDK1-4 inhibition, and PP2A reactivation that effectively eradicates brain tumor models by overcoming kinase inhibitor tolerance through combinatorial effects on signaling rewiring, OXPHOS, and apoptosis.

Functional testing of PI3K inhibitors stratifies responders to idelalisib and identifies treatment vulnerabilities in idelalisib-refractory/intolerant chronic lymphocytic leukemia

This study uses ex vivo drug sensitivity testing to identify treatment responses and vulnerabilities in chronic lymphocytic leukemia patients, showing that pan-PI3Ki and combinations with venetoclax can be effective in idelalisib-refractory/intolerant cases.

Development of Actionable Targets of Multi-kinase Inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells

The paper develops a platform to identify kinase targets of multi-kinase inhibitors in glioblastoma cells and finds AKT, PDK1, and PDK4 as targets of staurosporine derivatives that synergize with PP2A reactivation.

Optimized chemogenomic library design strategies for precision oncology

The paper presents strategies for designing optimized chemogenomic libraries for precision oncology, focusing on cancer-related targets and biological pathways.

Multi-modal meta-analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor

The paper integrates multi-modal omics data from cancer cell lines to identify ECHDC1 as a novel breast tumor suppressor and discover synthetic lethal interactions.

Crowdsourced mapping of unexplored target space of kinase inhibitors

The paper benchmarks predictive models for kinase inhibitor potencies using crowdsourced data and identifies new compound-kinase interactions.

DNA barcode-guided lentiviral CRISPRa tool to trace and isolate individual clonal lineages in heterogeneous cancer cell populations

This paper introduces a DNA barcode-guided CRISPRa tool for tracing and isolating individual clonal lineages in cancer cell populations, enabling unbiased analysis of subclonal evolution.

Control of MYC-dependent apoptotic threshold by a co-amplified ubiquitin E3 ligase UBR5

This study identifies UBR5 as a novel MYC ubiquitin ligase that regulates MYC protein stability and apoptotic threshold in cancer cells and breast tissue.

DNMT inhibitors increase methylation of CpGs related to p53 pathway genes in colon, lymphoma, bladder, ovarian, and breast cancer cells

The paper identifies CpGs that show increased methylation after DNMTi treatment in multiple cancer cell lines, particularly those related to the p53 pathway.